Tissue Regenix Group Share News (TRX)

Tissue Regenix has received a decision to grant a European patent covering the use of its technology, strengthening its plan to issue a global roll-out of dCELL. The group's dCELL technology will be used in creating tissue implants for bladder repair.dCELL removes DNA material from animal and human tissue leaving only remains, which the body will not reject, and can then be used to repair diseased or worn-out body parts.Chief Executive Officer Antony Odell said: "The global urology device market is one of the largest growth areas for the medical devices industry, and is estimated to be worth $8.6bn by 2022, driven by treatment demands for an ageing population."The York-based firm has partnered up with the University of Leeds to protectindividual products and processes.As of 10:22 the share price had risen 2.3% to 27p.WS